Fondazione Luigi Maria Monti
- Address
- lock Available on a paid plan
Skin and Connective Tissue Diseases
The Fondazione Luigi Maria Monti in Rome is running a broad portfolio in dermatology, with a strong focus on skin and connective tissue diseases such as bullous pemphigoid, epidermolysis bullosa, hidradenitis suppurativa, psoriasis, acne vulgaris, vitiligo, and diabetic foot ulcer. These studies mainly aim to improve symptom control, support wound healing, and assess the safety and effectiveness of new topical or systemic treatments.
- Long-term safety and disease control in bullous pemphigoid and hidradenitis suppurativa
- New treatment options for epidermolysis bullosa and related blistering disorders
- Therapies for psoriasis, acne vulgaris, and vitiligo aimed at improving skin symptoms and quality of life
- Wound-healing approaches for diabetic foot ulcer and other chronic skin conditions
Research at this site is centered on both long-term disease management and the evaluation of innovative skin-directed therapies for patients with chronic and often difficult-to-treat conditions.
Immune System Diseases
Clinical trials in immune system diseases at this site focus on conditions where the immune response plays a major role, including bullous pemphigoid, hidradenitis suppurativa, vitiligo, and psoriasis. The main purpose is to test whether new immune-targeted treatments can better control inflammation, reduce disease activity, and maintain results over time.
- Immune-modulating treatments for bullous pemphigoid and hidradenitis suppurativa
- Studies of vitiligo therapies designed to support repigmentation and disease stabilization
- Evaluation of psoriasis treatments that target immune pathways involved in chronic skin inflammation
- Research on the safety and durability of response for newer immunology-based therapies
These trials reflect a clear interest in refining immune-mediated disease care through treatments that may offer more sustained benefit and improved tolerability.
Neoplasms
The neoplasms portfolio at Fondazione Luigi Maria Monti includes studies in melanoma, Merkel cell carcinoma, cervical cancer, ovarian cancer, breast cancer, and other advanced solid tumors. These trials are designed to evaluate new cancer therapies, improve treatment effectiveness, and compare emerging combinations with current standards of care.
- New melanoma treatments for advanced, metastatic, and mutation-specific disease
- Immunotherapy studies in Merkel cell carcinoma and other difficult-to-treat cancers
- Trials in ovarian cancer, cervical cancer, and breast cancer focused on treatment response and disease control
- Research in broader solid tumors exploring whether novel immune-based approaches can improve outcomes
The cancer research program combines immunotherapy, targeted treatment strategies, and comparative effectiveness studies to address both common and rare advanced malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 31 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Boehringer Ingelheim Espana S.A.3trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Fondazione Luigi Maria Monti
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo. | Takeda Development Center Americas Inc. | Phase II | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 31 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 5 | Unknown | 2018-09-11 | 2023-11-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.